A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes and extranodal sites. The clinical course is typically aggressive.
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
The documentation for angioimmunoblastic T-cell lymphoma is limited due to its rarity and the complexities associated with its clinical characteristics. As AITL affects fewer individuals, systematic clinical studies have been sparse, which contributes to the gaps in understanding its genetic basis and clinical features. This situation can be frustrating, but ongoing research may provide more insights in the future.
To navigate your diagnosis of angioimmunoblastic T-cell lymphoma, consider seeking a hematologist or oncologist with expertise in T-cell lymphomas. These specialists can provide tailored treatment options and monitor your condition closely. Additionally, participating in clinical trials may offer access to new therapies; check the ClinicalTrials.gov link provided for opportunities. For further support, you can explore resources like the National Organization for Rare Disorders (NORD) at rarediseases.org, which can help connect you with additional information and support networks.
There are currently four orphan drugs designated for angioimmunoblastic T-cell lymphoma, indicating potential treatment avenues under development. Additionally, there are 31 active clinical trials investigating various aspects of this condition. For more information on these trials, you can visit the ClinicalTrials.gov search page: https://clinicaltrials.gov/search?cond=angioimmunoblastic%20T-cell%20lymphoma. This research landscape offers hope for improved management and treatment options.
Actionable guidance for navigating care for angioimmunoblastic T-cell lymphoma
To navigate your diagnosis of angioimmunoblastic T-cell lymphoma, consider seeking a hematologist or oncologist with expertise in T-cell lymphomas. These specialists can provide tailored treatment options and monitor your condition closely. Additionally, participating in clinical trials may offer access to new therapies; check the ClinicalTrials.gov link provided for opportunities. For further support, you can explore resources like the National Organization for Rare Disorders (NORD) at rarediseases.org, which can help connect you with additional information and support networks.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 3 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.